Citadel Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Citadel Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Sell	6,822 -3,442	-34%	-$120K	﹤0.01%	11446
2026 Q1	$353K	Buy	+10,264	New	+$351K	﹤0.01%	10104
2025 Q2	–	Sell	-7,961	Closed	-$219K	–	13384
2025 Q1	$219K	Buy	+7,961	New	+$220K	﹤0.01%	10279
2024 Q3	–	Sell	-12,698	Closed	-$346K	–	14555
2024 Q2	$346K	Buy	+12,698	New	+$340K	﹤0.01%	8856
2024 Q1	–	Sell	-7,963	Closed	-$212K	–	14857
2023 Q4	$212K	Buy	+7,963	New	+$201K	﹤0.01%	9844
2023 Q3	–	Sell	-22,990	Closed	-$602K	–	14561
2023 Q2	$602K	Buy	22,990 +14,557	+173%	+$385K	﹤0.01%	7527
2023 Q1	$220K	Buy	+8,433	New	+$226K	﹤0.01%	10012
2022 Q3	–	Sell	-19,181	Closed	-$507K	–	12951
2022 Q2	$507K	Sell	19,181 -2,287	-11%	-$60.5K	﹤0.01%	8611
2022 Q1	$571K	Buy	+21,468	New	+$554K	﹤0.01%	9075
2021 Q4	–	Sell	-23,129	Closed	-$591K	–	14128
2021 Q3	$591K	Buy	+23,129	New	+$607K	﹤0.01%	9459
2020 Q3	–	Sell	-32,687	Closed	-$748K	–	10269
2020 Q2	$748K	Buy	32,687 +16,445	+101%	+$364K	﹤0.01%	6358
2020 Q1	$324K	Sell	16,242 -837	-5%	-$18.3K	﹤0.01%	7190
2019 Q4	$398K	Buy	17,079 +3,156	+23%	+$68.7K	﹤0.01%	7163
2019 Q3	$284K	Buy	+13,923	New	+$287K	﹤0.01%	7629
2018 Q4	–	Sell	-10,650	Closed	-$248K	–	9322
2018 Q3	$248K	Buy	+10,650	New	+$247K	﹤0.01%	7884

Other funds holding FTXH

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors's FTXH Position: Q2 2026 in Review

Citadel Advisors reduced its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 34% in Q2 2026, selling an estimated $120K and leaving 6,822 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #11446.

Citadel Advisors first reported a position in FTXH in Q3 2018 and has held it in 15 quarters since. The position peaked at $748K in Q2 2020. 30 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

Citadel Advisors held 6,822 shares of First Trust Nasdaq Pharmaceuticals ETF worth $261K as of Q2 2026.
Citadel Advisors sold 3,442 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $120K.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11446 holding.
Citadel Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2018 and has held it in 15 quarters since.
Citadel Advisors's First Trust Nasdaq Pharmaceuticals ETF position peaked at $748K in Q2 2020.
30 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.